Liver Fibrosis Assessment in Diabetic Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

APP calculation for FIB-4: the investigators plan to use the smartphone App for FIB-4 calculation and notify the patients.

Standard Care (in control arm): The standard group proceeds as regular practice

Study summary

The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the identification, and management of liver fibrosis. This is to establish a patient-centered clinical pathway to identify patients with advanced fibrosis in type 2 diabetes patients. The investigators plan to conduct this randomized controlled trial of two groups: FIB-4 APP group and the standard care group. The primary end point is the referral rate of patients with advanced fibrosis (FIB-4 ≥ 2.67).

Eligibility

Primary outcome measure(s)

• The hepatology clinic referral rate if FIB-4 ≥ 2.67 (advanced fibrosis, F3) — through study completion, an average of 1 year
  Number of patients with FIB-4 ≥ 2.67 being referred to hepatology clinic, divided by total number of patients with FIB-4 ≥ 2.67.

Trial sites (1)

More National Taiwan University Hospital trials in Taiwan

Other trials for the same condition